Loading...
Loading...
BRTX| Name | Value |
|---|---|
| Revenues | 233.6K |
| Cost of Revenue | 18.2K |
| Gross Profit | 215.4K |
| Operating Expense | 2,502.3K |
| Operating I/L | -2,287.0K |
| Other Income/Expense | 1,195.6K |
| Interest Income | 158.5K |
| Pretax | -1,091.4K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -1,091.4K |
BioRestorative Therapies, Inc. is a life sciences company specializing in regenerative medicine products and therapies using adult stem cells. Its core programs focus on developing treatments for disc/spine disease and metabolic disorders. The company's revenue streams come from the development and commercialization of cell therapy candidates, such as BRTX-100 for lumbosacral disc disorders and ThermoStem for obesity and metabolic disorders. Additionally, it offers a curved needle device for delivering therapeutic products to the spine and discs. BioRestorative Therapies, Inc. has research and development agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and a research collaboration agreement with the University of Pennsylvania.
